Item 7.01 Regulation FD Disclosure.

On January 8, 2023, Agios Pharmaceuticals, Inc. (the "Company") issued a press release outlining its anticipated 2023 milestones and significant value-driving catalysts through 2026, which will be discussed at the Company's presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The slides to be presented by the Company at the 41st Annual J.P. Morgan Healthcare Conference are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.       Description

99.1          Press release dated on January 8, 2023

99.2          Presentation at the 41st Annual J.P. Morgan Healthcare Conference

 104        Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses